Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00688376
Recruitment Status : Completed
First Posted : June 2, 2008
Results First Posted : March 27, 2020
Last Update Posted : March 27, 2020
Sponsor:
Collaborator:
Eisai Limited
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.

Condition or disease Intervention/treatment Phase
Attention Impairment Drug: Donepezil hydrochloride Drug: Placebo Phase 3

Detailed Description:
This is a double-blind, placebo-controlled, parallel group study in pediatric subjects who have persistent attention impairment following treatment for cancer. This trial has three phases: (1) pre-randomization to establish eligibility, (2) a 12-week, double-blind, placebo-controlled, parallel-group phase with dose escalation based on body weight, (3) a 12-week, blinded extension phase during which all subjects will receive active drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
Actual Study Start Date : July 2, 2008
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 26, 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1 Drug: Donepezil hydrochloride

During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.

During the Blinded Extension Phase, all subjects will receive active treatment (donepezil).

Other Name: Aricept

Placebo Comparator: 2 Drug: Placebo

During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.

During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil).





Primary Outcome Measures :
  1. Change From Baseline in the Test of Variables in Attention-Continuous Performance Test (TOVA-CPT) "D-prime" Standard Score (SS) at Week 12 [ Time Frame: Baseline and Week 12 ]
    TOVA-CPT test has a standardized computer game-like format that tests attention and simple impulse control. It precisely measures a person's reaction time to clicking on correct targets versus incorrect targets. Scores are based on the number of "Hits" (correct responses), omission errors (failure to respond), commission errors/"False Alarms" (incorrect responses), response time, and sensitivity ("d-prime"). "D-prime" a dimensionless statistics is a measure of distractibility and reflects how well a person reacts correctly versus incorrectly. A higher value of "d-prime" is reached by having more "Hits" (correct response) and fewer "False Alarms" (incorrect response). Analysis was based on three factors: the "d-prime" standard score, reaction time variability standard score, and response time standard score. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.


Secondary Outcome Measures :
  1. Change From Baseline in the TOVA-CPT "D-prime" Standard Score (SS) at Week 6 [ Time Frame: Baseline and Week 6 ]
    TOVA-CPT test has a standardized computer game-like format that tests attention and simple impulse control. It precisely measures a person's reaction time to clicking on correct targets versus incorrect targets. Scores are based on the number of "Hits" (correct responses), omission errors (failure to respond), commission errors/"False Alarms" (incorrect responses), response time, and sensitivity ("d-prime"). "D-prime" a dimensionless statistics is a measure of distractibility and reflects how well a person reacts correctly versus incorrectly. A higher value of "d-prime" is reached by having more "Hits" (correct response) and fewer "False Alarms" (incorrect response). Analysis was based on three factors: the "d-prime" standard score, reaction time variability standard score, and response time standard score. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.

  2. Change From Baseline in the Reaction Time Variability Standard Score (RTVSS) and Response Time Standard Score (RTSS) at Weeks 6 and 12 [ Time Frame: Baseline, Weeks 6 and 12 ]
    The Reaction Time Variability is defined as the time measurement of how consistently the switch is pressed. The Response Time is the measurement of how fast or slow information is processed and responded to by the participant. The testing process was as described in a previous outcome measure. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.

  3. Change From Baseline in the Global Executive Composite Score, Behavioral Regulation Index, Metacognition Index, and Working Memory Subscale [ Time Frame: Baseline and Week 12 ]
    Behavioral Rating Inventory of Executive Functioning test evaluates impairment of executive function(planning and organization),memory,and sustained attention in children aged 5-18 years with wide range of developmental and acquired neurological conditions.Survey assess parent/guardian's perception of their child's executive functioning in home and school environments,which relate to daily function(as judged by parent).Each survey contains 86 items scored as;1(behavior is never a problem),2(behavior is sometimes a problem),or 3(behavior is often a problem).Data was presented as t-scores(raw scale scores are used to generate t-scores)for Global Executive Composite Score(t-score range 72-216),Behavioral Regulation Index(t-score range 28-84;inhibit,shift,and emotional control),Metacognition Inde (t-score range 44-132;initiate,working memory,plan/organize,organization of materials, and monitor),and Working Memory Subscale(t-score range 35-90).Higher scores indicate decline in performance.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. The subject must have received at least one cycle of chemotherapy and/or cranial radiation, and must have completed this treatment at least one year before screening takes place for entry into this study.
  2. Subjects may be male or female; age range: 6 - 17.5 years; weight ≥ 20 kg. They must be physically healthy and able to move about, with or without aids, must be living in the community, and must have adequate motor skills as shown by tests that will be given at the time of screening. The subject's eyesight and hearing must be good enough to allow cooperation with tests and physical examinations. Additionally, they must be able to swallow tablets.
  3. There must be subjective complaints by subject and/or parent of difficulties in school or other daily activities, possibly related to impairments in attention. These difficulties must have emerged after treatment for cancer and must still be present 12 months after cessation of treatment. There must also be objective evidence for this impairment, as shown by a test that will be given to the subject at the time of screening.
  4. The IQ must be >70 according to tests that will be given at the time of screening.
  5. The first language in which the subject learned to read and write must be one that uses Roman lettering (a, b, c, etc.) and Arabic numerals (1, 2, 3, etc.).
  6. The subject must not have previously taken any drugs in the class known as cholinesterase inhibitors.
  7. A parent or legal guardian must be available who is willing and able to complete all of the outcome measures, to administer medications, and to accompany the subject to the required clinic visits.
  8. Subjects with diabetes or thyroid disease may still be eligible if certain medical requirements are satisfied.
  9. Female subjects who could become pregnant must undergo pregnancy testing and must agree to use contraception.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  1. Inability to perform the required tests (for example, because of aphasia, motor deficits affecting the dominant hand, or mental retardation).
  2. Motor coordination not sufficient, according to tests to be conducted at the time of screening.
  3. Recurrence of cancer. If this happens, the subject will have to withdraw from the study.
  4. Mental retardation/developmental disability.
  5. Certain medications, such as methylphenidate, are not allowed during the study.
  6. Major depression.
  7. Problems with the digestive tract that could affect the subject's ability to absorb the study drug.
  8. Hypersensitivity to a chemical class known as piperidine derivatives.
  9. Certain other medical conditions as determined by clinical staff.
  10. Alcoholism, drug abuse, or organic brain disease other than that caused by the cancer or its treatment.
  11. Pregnancy, nursing, or unwillingness to undergo pregnancy testing if requested by clinical staff.
  12. Pregnancy, lactation or plans to become pregnant, or unwilling to take a screening Beta-human chorionic gonadotropin (ßhCG) test if a female >10 years of age.
  13. If sexually active, unwillingness to use birth control (males and females).
  14. Plans for certain types of elective surgery that would occur while the study is in progress.
  15. Plans for travel or other events that would interfere with the study schedule.
  16. Active treatment with another investigational drug within 3 months of the screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00688376


Locations
Layout table for location information
United States, California
Stanford, California, United States, 94305-5826
United States, Florida
Miami, Florida, United States, 33155
United States, Minnesota
Minneapolis, Minnesota, United States, 55404
United States, Missouri
Saint Louis, Missouri, United States, 63110
United States, New Jersey
New Brunswick, New Jersey, United States, 08903
United States, New York
Brooklyn, New York, United States, 11209
Great Neck, New York, United States, 10021
New York, New York, United States, 10065
United States, North Carolina
Chapel Hill, North Carolina, United States, 27514
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Texas
Dallas, Texas, United States, 75235
Houston, Texas, United States, 77030
Road Runner Research Ltd.
San Antonio, Texas, United States, 78258
Argentina
Cordoba Capital, Provincia De Cordoba, Argentina, 5000
Buenos Aires, Argentina, C1181ACH
Buenos Aires, Argentina, C1428AQK
Australia, New South Wales
Sydney, New South Wales, Australia, 2301
Westmead, Sydney, New South Wales, Australia, 2045
Canada, Alberta
Calgary, Alberta, Canada, T2T5C7
Chile
Antonio Varas, Providencia Santiago, Chile, 360
Santa Maria, Providencia Santiago, Chile, 0410
France
Vandoeurvre Les Nancy, France, 54511
Villejuif, France, 94805
Germany
Koeln, Germany, 50924
Netherlands
Amsterdam, Netherlands, 1081 HV
Groningen, Netherlands, 9713 GZ
Rotterdam, Netherlands, 3015 GJ
Utrecht, Netherlands, 3584 EA
Spain
Palma de Mallorca, Spain, 07198
Valencia, Spain, 46009
United Kingdom
Sutton, Surrey, United Kingdom, SM2 5PT
Sponsors and Collaborators
Eisai Inc.
Eisai Limited

Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT00688376    
Obsolete Identifiers: NCT00687635
Other Study ID Numbers: E2020-G000-333
E2020-G000-334 ( Registry Identifier: NCT00687635 )
2007-005435-28 ( EudraCT Number )
First Posted: June 2, 2008    Key Record Dates
Results First Posted: March 27, 2020
Last Update Posted: March 27, 2020
Last Verified: November 2015
Keywords provided by Eisai Inc.:
Attention
cancer
chemotherapy
donepezil
acetylcholinesterase
inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents